Clinical Trial

Isoleucine Addition Treatment Effects in a Controlled Diet Study

Study acronym: ISOLATE
Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
The study was not funded.
Summary
The primary purpose of this study is to determine whether isoleucine repletion attenuates increases in insulin sensitivity typically observed when people with obesity follow a healthy, low-isoleucine diet.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-16
notable Enrollment reduced: 40 -> 0 participants 2026-04-16
Trial Details
NCT Number NCT07329088
Lead Sponsor Jean L. Fry
Collaborators: National Institute of General Medical Sciences (NIGMS)
Conditions Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight
Start Date 2026-05-04
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15